CEO Message

The Foundation for Biomedical Research and Innovation at Kobe (FBRI) was established in 2000 as a core organization to support the cluster of bio-medical companies in Kobe, Japan. The Research & Development Center for Cell Therapy (RDC) was established as the fourth center in FBRI in 2015. The goals of the RDC are to ensure the quality of cell products used in cell & gene therapy to facilitate regulatory approval and to provide cell manufacturing services as a CMO/CDMO for domestic and global biotech and pharma companies.

 

Beginning in April 2023, Cyto-Facto Inc. will take over the business activities of RDC as an FBRI spinout company. Cyto-Facto Inc. will take full responsibility for meeting the demands of society and the healthcare industry for reliable cell & gene therapy products.

 

We will continuously improve our service and our manufacturing technology to support the health of society by providing quality cell & gene therapy products to patients in a timely manner.





Shin Kawamata, MD, PhD

Representative Director, Chief Executive Officer

Company

Name Cyto-Facto Inc.
Representative Shin Kawamata, MD, PhD, CEO
Location Shimin Byoin Mae Bldg 3F, 2-1-11, Minatojima-minamimachi, Chuo-ku, Kobe, Japan
Establishment October 18, 2022
Employees 65 (as of April 1st, 2024)

Access Map

PAGE TOP